Previous studies have shown that serum GFAP is elevated in patients with brain or spinal cord diseases compared with healthy controls [8,9,13] and is positively correlated with IL-6, a marker of inflammation, in patients with hepatic encephalopathy [19]. Here, GFAP is linked to spinal cord disorder.